Aurora-B (06681) signed a strategic cooperation agreement with Raihus Spall to expand the Singaporean market and promote international layout

According to the Zhitong Finance App, Brain Action Aurora-B (06681) announced that the company recently signed a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings (Natural Health Solutions Programme Group Holdings, Laihe Sibao). The two sides will cooperate in product promotion and market expansion in the Singapore market to jointly promote the development of the digital health industry.

As one of Asia's advanced economies, Singapore is facing the challenge of a rapidly ageing population. According to Singapore government data, the proportion of people aged 65 and over continues to rise, and the incidence of cognitive impairment (dementia) in old age is also significant. The Singapore Government actively promotes national projects such as the “Health SG” program and “Disability Friendly Singapore” to encourage early screening and full-cycle health management, providing a good policy environment and market foundation for digital therapy products for cognitive impairment.

As a pioneer in the digital therapy market for cognitive impairment in China, the core product “Brain Function Information Management Platform Software System” is the first digital therapy product for cognitive impairment approved by regulations in China, and has entered the provincial medical insurance reimbursement catalogue in 30 provinces in China. A professional health management service organization headquartered in Singapore. It has a self-developed SC Health AI digital health assessment system. The service network covers the community medical and health management market.

According to the agreement, the cooperation between the two parties mainly includes the following: (I) Product promotion cooperation: the company is responsible for the localization of digital therapy products for cognitive impairment in Singapore, system implementation and personnel training support; Laihe Sibao will rely on all of its offline stores and member resources to recommend the company's products to target users, and is responsible for the whole process of services, including product introduction, trial guidance, purchase conversion and after-sales support. (II) Market development collaboration: The two sides integrate resources such as products, channels, brands and technology to jointly explore the Singapore market, focusing on promoting the company's products into Singapore's leading private hospitals and public hospital systems, and enhancing the application and popularization of products in the local medical system.

The board of directors believes that this cooperation will bring long-term development opportunities to the company and create sustainable value for shareholders. Specifically: (I) Deepen the international layout and expand overseas markets: the company has begun product promotion and operation in Hong Kong and Macau, China, and has initially accumulated overseas market experience. This collaboration with Raihe Sibao marks the official launch of the company's market layout and business development in Southeast Asia. This move helps to systematically export the digital therapy experience and technology system accumulated by the company in the Chinese market to other large-scale and policy-supported regional markets, further expand the company's international brand influence and business coverage, and enhance global influence. (II) Enhancing brand influence and business network: This cooperation has further strengthened the company's brand authority and professional image in the field of digital healthcare. With the health management network in Singapore, the company can accelerate the implementation of products in local medical institutions, shorten the market introduction cycle, and expand diversified markets such as digital health management.